Cargando…

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib

BACKGROUND: Inflammatory myofibroblastic tumor (IMT) is an ultra‐rare soft tissue neoplasm associated with fusion proteins encompassing the anaplastic lymphoma kinase (ALK) protein fused to a variety of partner proteins. Data regarding response to ALK‐targeting agents based on fusion partner is limi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sunga, Cass G. G., Higgins, Michael S., Ricciotti, Robert W., Liu, Yajuan J., Cranmer, Lee D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026288/ https://www.ncbi.nlm.nih.gov/pubmed/36754839 http://dx.doi.org/10.1002/cnr2.1792

Ejemplares similares

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report
por: Lin, Jieheng, et al.
Publicado: (2022)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

Recurrent infantile inflammatory myofibroblastic tumor of mesentery––Case report and review of imaging findings
por: Gupta, Aarushi, et al.
Publicado: (2020)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2023)

ALK ‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib
por: Song, Lianxi, et al.
Publicado: (2022)

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib
por: Guo, Weihong, et al.
Publicado: (2022)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Epithelioid cell histiocytoma with SQSTM1-ALK fusion: a case report
por: Nakayama, Ryuko, et al.
Publicado: (2018)

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
por: Zhai, Xiaoqian, et al.
Publicado: (2022)

Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing
por: Zhang, Chenlu, et al.
Publicado: (2020)

Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib
por: Carballo, Erica V., et al.
Publicado: (2022)

A Novel LINC00478/LINC01549 Intergenic Region-ALK Fusion Responded Well to Alectinib in a Patient With Lung Adenocarcinoma
por: Peng, Wei, et al.
Publicado: (2020)

Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
por: Mansfield, A. S., et al.
Publicado: (2016)

Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report
por: Yan, Lingxin, et al.
Publicado: (2023)

Inflammatory Myofibroblastic Tumor of the Upper Airways Harboring a New TRAF3-ALK Fusion Transcript
por: Di Ruscio, Valentina, et al.
Publicado: (2021)

A recurrent inflammatory myofibroblastic tumor patient with two novel ALK fusions: a case report
por: Xu, Xiumei, et al.
Publicado: (2022)

Inflammatory myofibroblastic tumor of the urinary bladder with FN1‑ALK gene fusion: A case report
por: Son, Seung-Myoung, et al.
Publicado: (2023)

ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma
por: Jiang, Quan, et al.
Publicado: (2017)

Intraosseous inflammatory myofibroblastic tumor of the mandible with a novel ATIC-ALK fusion mutation: a case report
por: Tateishi, Yoko, et al.
Publicado: (2016)

Thoracic SMARCA4-Deficient Undifferentiated Tumor With ALK Fusion Treated With Alectinib Achieved Remarkable Tumor Regression: Case Report
por: Sheng, Jin, et al.
Publicado: (2023)

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review
por: Isaka, Yuri, et al.
Publicado: (2023)

ALK negative inflammatory myofibroblastic tumor of the orbit: A masquerading entity
por: Dutta, Vibha, et al.
Publicado: (2014)

ALK Negative Inflammatory Myofibroblastic Tumor Synchronous with Classical Hodgkin Lymphoma
por: Sandoval, Letícia, et al.
Publicado: (2019)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Inflammatory myofibroblastic tumor of the small-bowel mesentery: A case report of nonspecific clinical presentation and a review of the literature
por: Koyuncuer, Ali
Publicado: (2014)

Case Report: Efficacy of ensartinib treatment in pulmonary inflammatory myofibroblastic tumor with a rare GCC2-ALK fusion
por: He, Wenguang, et al.
Publicado: (2022)

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
por: Zhu, Lucheng, et al.
Publicado: (2022)

A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018)

An Unusual Case of Systemic Inflammatory Myofibroblastic Tumor with Successful Treatment with ALK-Inhibitor
por: Jacob, Sanjivini V., et al.
Publicado: (2014)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report
por: Ning, Shangkun, et al.
Publicado: (2021)

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
por: Zeng, Hao, et al.
Publicado: (2021)

A malignant inflammatory myofibroblastic tumor of the hypopharynx harboring the 3a/b variants of the EML4-ALK fusion gene
por: Muscarella, Lucia Anna, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h2cnd55hum7l5etgvh7lu1csf8